:be Aktie 113268981 / AT0000A2SGH0
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
|
31.12.2025 23:30:00
|
Where Will Pfizer Be in 5 Years?
Pfizer (NYSE: PFE) is one of the world's largest drugmakers. That doesn't guarantee the company's success, but it does provide the company with some important long-term advantages.Currently, however, Pfizer is facing significant headwinds, and the stock has declined roughly 60% from its 2021 highs. For long-term investors who can handle a little adversity, this could be a buying opportunity.A stock doesn't lose 60% of its value randomly, and Pfizer is dealing with very real issues right now. However, some of that drop is attributable to investor enthusiasm running a bit too hot during the coronavirus pandemic. At that point, Pfizer was one of the few pharmaceutical companies that was offering a COVID-19 vaccine.Continue readingWeiter zum vollständigen Artikel bei MotleyFool